Qiagen expands QIAstat-Dx portfolio after FDA clearance for Qiagen stock
Published on 10/18/2026 at 17:44 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSQIAGEN expands diagnostic testing
- QIAGEN announced FDA clearance for a new QIAstat-Dx panel on September 28, 2026.
- The new panel identifies 13 gram-negative bacterial targets and 18 antimicrobial resistance markers.
- The complete portfolio covers 33 pathogen targets and 28 resistance markers.
QIAGEN announced on September 28, 2026, that U.S. laboratories had access to its complete QIAstat-Dx bloodstream infection portfolio after the U.S. Food and Drug Administration cleared a new panel, according to the QIAGEN release.
Market context: Market report DAX.
Weekend trading
The next price is shown from the start of trading by the continuously updated real-time quote of Qiagen stock.
QIAGEN diagnostic portfolio
The QIAstat-Dx BCID GN Plus AMR Panel identifies 13 gram-negative bacterial pathogen targets and 18 antimicrobial resistance markers. It complements the QIAstat-Dx BCID GPF Plus AMR Panel, which identifies gram-positive bacteria and fungi, the company said in its September 28 release.
Together, the two panels cover 33 pathogen targets and 28 antimicrobial resistance markers. Both panels deliver results in about one hour, according to QIAGEN.
Dates of the coming week
QIAGEN’s September 28 announcement also said that the QIAstat-Dx system was available in more than 100 countries and had more than 5,200 cumulative placements at the end of 2025. The release did not identify a further company date for the coming week.
